机构：[1]Fujian Med Univ, Affiliated Hosp 1, Nucl Med, Fuzhou, Fujian, Peoples R China[2]Beijing Tongren Hosp, Nucl Med, Beijing, Peoples R China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]1st Hosp Nanjing, Nucl Med, Nanjing, Jiangsu, Peoples R China[4]Peking Univ, Med Isotopes Res Ctr, Beijing, Peoples R China[5]Beijing Union Med Coll Hosp, Nucl Med, Beijing, Peoples R China
出处：
ISSN：
基金：
Capital Special Project for Featured Clinical Application in 2011 [Z111107058811096]; National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [30870725, 30870728, 30930030, 30900373, 81000625, 81028009, 81171369]; "973" projectNational Basic Research Program of China [2011CB707703]; Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2009ZX09103-733]; Fujian Provincial Department of Science [2010J01154]; Technology and Department of Education [JB09114]
第一作者机构：[1]Fujian Med Univ, Affiliated Hosp 1, Nucl Med, Fuzhou, Fujian, Peoples R China
推荐引用方式(GB/T 7714)：
Miao Weibing,Zheng Shan,Dai Haojie,et al.99mTc-3PRGD2 as a novel tracer for integrin receptor imaging of lung cancer and bone metastasis[J].JOURNAL OF NUCLEAR MEDICINE.2012,53:
APA：
Miao, Weibing,Zheng, Shan,Dai, Haojie,Wang, Feng,Jia, Bing&Zhu, Zhaohui.(2012).99mTc-3PRGD2 as a novel tracer for integrin receptor imaging of lung cancer and bone metastasis.JOURNAL OF NUCLEAR MEDICINE,53,
MLA：
Miao, Weibing,et al."99mTc-3PRGD2 as a novel tracer for integrin receptor imaging of lung cancer and bone metastasis".JOURNAL OF NUCLEAR MEDICINE 53.(2012)
医学